Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 11/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4874767 | 0.82 | CASP1 (0.44) | KIF11 | |
| SCHEMBL5476864 | 0.80 | CTSK (0.41) | ADORA1CTSSCTSK | |
| SCHEMBL5476420 | 0.77 | KCNN4 (0.41) | KIF11ADORA1CTSK | |
| SCHEMBL5475919 | 0.77 | CYP4F2 (0.54) | — | |
| SCHEMBL31306433 | 0.73 | KIF11 (0.49) | KIF11CETPFFAR1 | |
| SCHEMBL16136803 | 0.72 | DRD2 (0.42) | — | |
| SCHEMBL11204953 | 0.72 | KAT6A (0.43) | KIF11CETP | |
| SCHEMBL688437 | 0.71 | CETP (0.50) | KIF11CETPCTSSCTSK | |
| SCHEMBL688438 | 0.71 | CETP (0.50) | KIF11CETPCTSSCTSK | |
| SCHEMBL11527555 | 0.70 | KIF11 (0.51) | KIF11CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | KIF11 4127/4885CETP 79/4885ADORA1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.